Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Babar Basir , Karim Al-Azizi Added: 1 month ago
ACC 2026 — Drs Karim Al-Azizi (Baylor Scott & White The Heart Hospital, Plano) and Babar Basir (Henry Ford Hospital, US) deliver a short, front-line interventional view of the STEMI Door-to-Unload (STEMI-DTU) trial (NCT03000270), making this an efficient 5-minute update for cardiologists and cath lab teams.STEMI-DTU randomised haemodynamically stable patients aged 18–85 years with a first acute… View more
Author(s): Alfonso Ielasi Added: 1 year ago
In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). View more
Author(s): Mohaned Egred , Juan Luis Gutiérrez-Chico , Carlo Tumscitz , et al Added: 1 month ago
Welcome to our exclusive video series featuring leading interventional cardiologists sharing their real-world experiences with Excimer Laser Coronary Atherectomy (ELCA). Through clinical insights, case discussions and practical tips, these videos reveal how ELCA plays a critical role in tackling today's most challenging lesions – from in-stent restenosis to undilatable, uncrossable lesions and… View more
Author(s): Santiago Garcia Added: 10 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings… View more
Author(s): Added: 10 months ago
New York Valves 25 - Quantitative findings from Tri-QOL showed a strong correlation between tricuspid regurgitation (TR) reduction and KCCQ improvement after transcatheter tricuspid valve intervention (TTVI).Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, Kansas City, US) discusses findings from a quantitative analysis from the Tri-QOL study which aimed to assess the optimal result… View more
Author(s): Tatsuya Nakama Added: 1 year ago
LINC 2025 - Outcomes from the GRIFFIN study suggest post-procedural functional flow reserve (FFR) could be a useful predictor of restenosis after drug-coated balloon (DCB) angioplasty for superficial femoral artery (SFA) lesions. Restenosis patients showed significantly lower FFR values than non-restenosis patients, and the study resulted in a good FFR cut-off value of restenosis after DCB… View more
Author(s): Julien Dreyfus Added: 11 months ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating… View more
Author(s): Naoki Hayakawa Added: 1 year ago
LINC 2025 - Three-year outcomes of drug-coated balloon (DCB) treatment for femoropopliteal (FP) chronic total occlusive (CTO) lesions show low patency rates in patents with multiple independent risk factors for patency loss. However, patients without risk factors achieved acceptable patency rates and clinical outcomes of freedom from clinically driven target lesion revascularization, reoclussion… View more
Author(s): Denisa Muraru Added: 4 months ago
Discover why tricuspid regurgitation aetiology matters for patient outcomes and intervention strategies with Prof Denisa MuraruThis presentation, part of a comprehensive series on complex cases in interventional cardiology, explores how understanding TR mechanisms directly impacts diagnosis, treatment selection, and clinical prognosis.Prof Muraru addresses the critical heterogeneity in TR… View more